Fashionably Early: When to Make Your Case to CMS
This article was originally published in RPM Report
Executive Summary
Manufacturers used to look at Medicare coverage as an afterthought to FDA approval. Now, CMS has a simple message for biopharmaceutical companies: plan ahead. CMS senior officials explain what manufacturers should be thinking about when they come to the agency about reimbursing new products.
You may also be interested in...
The Devil is in the Details: CMS To Flesh Out Committee's Research Role
CMS plans to be more open about how the Medicare coverage advisory committee will score research priorities after comments from industry. Stakeholders know the process won't any easier after Election Day.
FDA-CMS Parallel Reviews: Too Close for Comfort?
Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.
FDA-CMS Parallel Reviews: Too Close for Comfort?
Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.